Oferta tecnológica

NAME OF PROJECT OR TECHNOLOGY	BRIEF DESCRIPTION	TECHNOLOGY TYPE	ORIGIN	APPLICATION OR THERAPEUTIC AREA	STAGE	INTELLECTUAL PROPERTY STATUS	TARGET MARKET (IF KNOWN)
Method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk	1. DIAGNOSTICS	DIAGNOSTICS	CLINIC	INFLAMMATORY & IMMUNE SYSTEM	PRECLINICAL & PROTOTYPE	PATENTS GRANTED	In-vitro diagnostics , Allergy In Spain 11.250 new cases/year; 3.000 persistent
Composite scaffolds for tissue regeneration	5. MEDICAL DEVICES	DRUG DELIVERY	CLINIC	NEUROLOGICAL & STROKE	- PRECLINICAL & PROTOTYPE	PATENTS GRANTED	Various diseases that affect the central nervous system that need regenerating neural tracts
Pharmaceutical Compotisiton For The Treatment Of Cardiovascular Diseases	3. DRUG DELIVERY	DRUG DELIVERY	CLINIC	CARDIOVASCULAR	- DISCOVERY & CONCEPT	PATENTS GRANTED	Treatment of hypercholesterolemia alternative to stains
Penélope: A clinical support tool for data exploitation in research, innovation and management	Penélope is a role-based access web tool which support all health care stakeholders by given them a smart data-warehouse with integrated, normalized and standardised real-time data acquired from different sources (e.g laboratory, pharma and electronic health records). Health care professionals and patients interact through a chronic and outpatient-oriented, user-friendly interface, with a high level of codification and visualization. Penélope grows daily and facilitates instant, updated new data for different users. Not only patients and physicians, but also researchers, academics, managers, payers and almost every component involved in the health care system can benefit from the data stored in Penélope. The access to information is adapted depending on the professional profile, providing the most helpful tools for each stakeholder: while Penélope help managers who need data for elaborating statistics, it also helps innovators who need data for developing machine learning models, and physicians who want to see the response to different therapeutics. Penélope is designed in a modular way to ensure interoperability and good performance in multiple platforms using already	DIGITAL HEALTH, BIG DATA, ARTIFICIAL INTELLIGENCE	CLINIC	INFLAMMATORY & IMMUNE SYSTEM	- PATHWAY (CLASS) & STATUS		Penélope solution is oriented to managers and administrators who want to optimize the quality of data from the very first step, while supplying, at the same time, a data-warehouse to the rest of stakeholders which can be used for different purposes depending on the professional roles needs.

NAME OF PROJECT OR TECHNOLOGY	BRIEF DESCRIPTION	TECHNOLOGY TYPE	ORIGIN	APPLICATION OR THERAPEUTIC AREA	STAGE	INTELLECTUAL PROPERTY STATUS	TARGET MARKET (IF KNOWN)
	developed and well-extended standards like HL7 and ICD-10. The entity framework core technology employed in Penélope development also facilitates the scability of this product, as well as its implementation and future updates.						
Method for the identification of cardiac fibrillation drivers and/or the footprint of rotational activations using single optical or electrical signals without requiring panoramic simultaneous acquisition	Method for the identification of cardiac fibrillation drivers and/or the footprint of rotational activations using single optical or electrical signals without requiring panoramic simultaneous acquisition	MEDICAL DEVICES	LAB	CARDIOVASCULAR	- PRECLINICAL & PROTOTYPE	PATENTS GRANTED	This invention relates to determination of ablation sites for ablation treatments applied to cardiac tissue, in overall burden of atrial fibrillation
SEGTNAN: Development of an algorithm to optimize SARS-CoV-2 pool testing based on quantitative variables from each individual patient	Group- testing denotes sampling biological specimens from individual patients and pooling them into groups. Use of group testing can reduce tests used with 93%, reduce economic test-burden eight-fold and increase test-capacity 133% for the SARS-CoV-2 virus. However, to this date worldwide differences in prevalence of SARS-CoV-2, difference in PCR-equipment and national politics leaves how to pool the SARS-CoV-2 tests based on scientific assumptions. Our results demonstrate a method that individualizes how to pool SARS-CoV-2 tests based on quantitatively variables from each individual patient. In comparison with individual PCR tests, the invention permits reducing the number of PCR tests in thermal cyclers by 77.42 %, thus substantially reducing the required test resources. Such savings would mean more than 500 million DKK in a week for the Danish govern.	1DIAGNOSTICS	DEPARTMENT	INFECTION	- PATHWAY (CLASS) & STATUS	PATENTS GRANTED	The customers are global COVID-19 test sites which include both public and private organizations. The primary target customers are laboratories who perform analysis of COVID-19 test samples since they can use the Sophia AI software to predict the optimal group size. The secondary target customers are private companies that can perform group testing and want to sell COVID-19 tests at a cheaper price. Lastly, the solution could also be offered to third world countries since they can utilize test capacity better.